Financial Ratios

JAGSONPAL PHARMACEUTICALS LTD.

NSE : JAGSNPHARMBSE : 507789ISIN CODE : INE048B01027Industry : Pharmaceuticals & DrugsHouse : Jagsonpal
BSE279.85-0.55 (-0.2 %)
PREV CLOSE ( ) 280.40
OPEN PRICE ( ) 279.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1411
TODAY'S LOW / HIGH ( )275.60 282.65
52 WK LOW / HIGH ( )270.05 513.9
NSE276.60-4.1 (-1.46 %)
PREV CLOSE( ) 280.70
OPEN PRICE ( ) 284.90
BID PRICE (QTY) 276.60 (22)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 26509
TODAY'S LOW / HIGH( ) 273.70 284.90
52 WK LOW / HIGH ( )273.6 514.85
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)10.207.206.513.002.75
   CEPS(Rs)10.667.786.933.443.14
   DPS(Rs)5.004.001.000.500.25
   Book NAV/Share(Rs)57.3050.6843.5539.3936.89
   Tax Rate(%)23.2329.2322.0116.4019.85
Margin Ratios
   Core EBITDA Margin(%)13.2810.3210.155.385.60
   EBIT Margin(%)13.7011.1111.916.265.84
   Pre Tax Margin(%)13.5410.9911.645.945.40
   PAT Margin (%)10.397.789.084.964.33
   Cash Profit Margin (%)10.868.419.655.684.93
Performance Ratios
   ROA(%)14.2911.2410.905.535.43
   ROE(%)18.8915.2815.707.887.72
   ROCE(%)24.1521.2319.439.469.80
   Asset Turnover(x)1.381.441.201.111.26
   Sales/Fixed Asset(x)5.634.103.182.803.07
   Working Capital/Sales(x)1.882.952.352.572.40
Efficiency Ratios
   Fixed Capital/Sales(x)0.180.240.310.360.33
   Receivable days25.8721.2633.1348.5750.22
   Inventory Days35.7844.7657.3471.3892.03
   Payable days68.4475.0867.2476.5652.49
Valuation Parameters
   PER(x)28.4243.5712.225.819.55
   PCE(x)27.2040.3111.495.088.37
   Price/Book(x)5.066.191.830.440.71
   Yield(%)1.721.281.262.870.95
   EV/Net Sales(x)2.723.660.820.070.20
   EV/Core EBITDA(x)16.1727.996.601.053.17
   EV/EBIT(x)18.3129.576.921.173.50
   EV/CE(x)3.184.650.940.080.25
   M Cap / Sales3.213.781.110.290.41
Growth Ratio
   Net Sales Growth(%)8.7915.7718.53-4.9531.84
   Core EBITDA Growth(%)40.1821.22112.252.74201.07
   EBIT Growth(%)30.8020.29125.461.85188.87
   PAT Growth(%)41.7210.53116.739.07162.47
   EPS Growth(%)41.7210.53116.739.08162.47
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.060.060.04
   Current Ratio(x)4.893.402.982.793.46
   Quick Ratio(x)4.312.532.251.942.30
   Interest Cover(x)85.2894.4843.5919.3113.08
   Total Debt/Mcap(x)0.000.000.030.140.05

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.